Clinical trial
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251 · Hoffmann-La Roche, Industry · Recruiting
Key facts
| NCT number | NCT03683251 |
|---|---|
| Title | Extension Study for the Port Delivery System With Ranibizumab (Portal) |
| Official title | A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal) |
| Acronym | Portal |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neovascular Age-Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | PDS Implant with Ranibizumab 100 mg/mL |
| Enrollment | 1,000 |
| Start date | Sep 20, 2018 |
| Primary completion | Oct 31, 2029 |
| Completion | Oct 31, 2029 |
| First posted | Sep 25, 2018 |
| Last update posted | Feb 2, 2026 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, France, Germany, Israel, Italy, Spain, Switzerland, Taiwan and 3 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: